6 results about "Zinc binding" patented technology

There is provided inter alia an aqueous liquid pharmaceutical formulation comprising (i) an insulin compound, (ii) ionic zinc, (iii) a zinc binding species at a concentration of 1 mM or more selected from species having a log K with respect to zinc ion binding in the range 4.5-12.3 at 25° C., and (iv) a non-ionic surfactant which is an alkyl glycoside; and wherein the formulation is substantially free of EDTA and any other zinc binding species having a log K with respect to zinc ion binding of more than 12.3 at 25° C.

The present invention relates to a novel zinc-binding dehydrogenase variant and a method of producing an L-aromatic amino acid using the same. The zinc-binding dehydrogenase variant is obtained by substituting one or more amino acids in the amino acid sequence constituting zinc-binding dehydrogenase to change the enzymatic activity of the zinc-binding dehydrogenase, and a recombinant microorganism comprising the variant is capable of efficiently producing an L-aromatic amino acid.

The invention discloses electroplating liquid for preparing an aqueous zinc ion battery negative electrode and application of the electroplating liquid, and relates to the technical field of aqueous zinc ion battery negative electrodes. Aiming at the problems of dendritic crystal growth and the like of a zinc negative electrode in an aqueous zinc ion battery, the electroplating liquid is optimized by introducing specific additives, namely L-xylose (L-Xylose) and ribose (Ribose), and the distribution and thickness of a zinc coating on the surface of a copper foil can be adjusted by changing current and electroplating time. According to the zinc negative electrode material prepared by using the electroplating solution, due to the unique petal-shaped three-dimensional structure, more zinc ion deposition sites can be provided, the specific surface area of an electrode can be increased, and the uniformity and reversibility of zinc deposition are remarkably improved. The binding energy of copper and zinc in the copper-zinc compound is high, agglomeration of zinc atoms can be reduced, the petal-shaped copper-zinc compound can reconstruct a solvation structure of Zn < 2 + >, a desolvation energy barrier is reduced, an electrolyte interface double-electrode-layer structure is optimized, and zinc dendrite growth is inhibited, so that the efficiency of the battery is improved, and the service life of the battery is prolonged.

The present invention relates to a novel zinc-binding dehydrogenase variant and a method of producing an L-aromatic amino acid using the same. The zinc-binding dehydrogenase variant is obtained by substituting one or more amino acids in the amino acid sequence constituting zinc-binding dehydrogenase to change the enzymatic activity of the zinc-binding dehydrogenase, and a recombinant microorganism comprising the variant is capable of efficiently producing an L-aromatic amino acid.

The present invention relates to a Vitis sp. plant or part thereof having a reduced level of flower sex polypeptide (FSL) activity compared to a corresponding wild-type Vitis sp. plant or part thereof having an FSL locus genotype that confers a hermaphrodite flower phenotype, wherein said Vitis sp. plant or part thereof comprises an FSL locus comprising a polynucleotide sequence encoding the FSL polypeptide, and wherein the polynucleotide sequence comprises a genetic modification in the region encoding a plant domain with an AT₂-rich zinc-binding sequence (PLATZ) of the FSL polynucleotide in relation to a corresponding polynucleotide sequence of a wild-type Vitis sp. FSL locus allele that confers a hermaphrodite flower phenotype when expressed, whereby the genetic modification causes a male reproductive part of a flower in the Vitis sp. plant to be expressed.or part of it is not functional.

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: (I) or a pharmaceutically acceptable salt there- of, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor, wherein the compound of Formula I or pharmaceutically ac- ceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.